Clinical Trial Update: Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating Rft5-Dga to deplete alloreactive cells in Fanconi anemia patients after haploidentical stem cell transplantation was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fanconi Anemia

Drugs mentioned

• Rft5-Dga

Snippet

Sponsor: Baylor College of Medicine | Conditions: FANCONI ANEMIA | Phase 1 | Status: TERMINATED